Tirzepatide is a novel synthetic peptide acting as a dual agonist at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism of action distinguishes tirzepatide from single-receptor GLP-1 agonists, offering researchers a unique tool for investigating incretin-based metabolic pathways and their downstream effects on insulin secretion, appetite regulation, and lipid metabolism.
In preclinical and clinical research settings, tirzepatide has demonstrated significant interest in the study of type 2 diabetes models, obesity-related metabolic dysfunction, and cardiovascular risk factor modulation. Its dual receptor engagement amplifies insulinotropic responses in a glucose-dependent manner, reducing the risk of hypoglycaemia in experimental models whilst simultaneously influencing gastric emptying and energy homeostasis.
Peptician supplies Tirzepatide 50mg as a lyophilised powder of greater than 98% purity, suitable for in vitro and preclinical in vivo research applications.
Store lyophilised product at -20°C, protected from light and moisture. Upon reconstitution, store at 4°C and use within 28 days.
Molecular Formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight
4813.5 g/mol
Purity
>98%
CAS Number
2023788-19-2
Form
Lyophilised Powder
Research Applications
Metabolic disorder research, Type 2 diabetes models, Obesity and body composition studies, Cardiovascular risk factor investigation, Incretin biology, Appetite and energy homeostasis research
For research purposes only. Not for human use. This product is intended solely for in vitro and preclinical research applications by qualified professionals.
Reviews
There are no reviews yet.